Fig 2 - uploaded by Jens Velde Andersen
Content may be subject to copyright.
The glutamate-glutamine cycle is closely linked to cellular energy metabolism. Glutamate and glutamine are extensively recycled between neurons and astrocytes in a process known as the glutamate-glutamine cycle. Glucose is the primary substrate for the synthesis of glutamate. Furthermore, glutamate synthesis and metabolism is closely connected to both neuronal and astrocytic energy metabolism through the TCA cycle. Astrocytes express the major anaplerotic enzyme in the brain pyruvate carboxylase (PC) catalyzing the conversion of pyruvate to oxaloacetate which is essential for de novo glutamate synthesis. This pathway is absent in neurons and pyruvate must enter the TCA cycle via pyruvate dehydrogenase (PDH). Glutamate is released to the synaptic cleft from vesicles in the presynaptic neurons, hereby mediating excitatory signals in the postsynaptic neuron. Glutamate is primarily removed from the synapse by astrocytic uptake via the transporters GLT-1 and GLAST. However, a fraction is also removed by neuronal uptake primarily mediated by GLT-1 activity. In the astrocyte, glutamate is converted into glutamine by the enzyme glutamine synthetase (GS) which is only found in astrocytes. Glutamine may be released from astrocytes through SNAT3/5 and is taken up by neurons primarily by SNAT1/7/8. Once taken up into the neurons, glutamine is converted by phosphate-activated glutaminase (PAG) into glutamate and the cycle is thereby completed. Note that SNAT1/7/8 are localized in the axon terminal for diagrammatic purposes to indicate expression in neurons. The SNATs expressed specifically in axon terminals have not been definitively identified (Conti and Melone, 2006; Erickson, 2017). Glutamate is also oxidatively metabolized in the TCA cycle in both neurons and astrocytes, primarily via the enzymes aspartate aminotransferase (AAT) and glutamate dehydrogenase (GDH).

The glutamate-glutamine cycle is closely linked to cellular energy metabolism. Glutamate and glutamine are extensively recycled between neurons and astrocytes in a process known as the glutamate-glutamine cycle. Glucose is the primary substrate for the synthesis of glutamate. Furthermore, glutamate synthesis and metabolism is closely connected to both neuronal and astrocytic energy metabolism through the TCA cycle. Astrocytes express the major anaplerotic enzyme in the brain pyruvate carboxylase (PC) catalyzing the conversion of pyruvate to oxaloacetate which is essential for de novo glutamate synthesis. This pathway is absent in neurons and pyruvate must enter the TCA cycle via pyruvate dehydrogenase (PDH). Glutamate is released to the synaptic cleft from vesicles in the presynaptic neurons, hereby mediating excitatory signals in the postsynaptic neuron. Glutamate is primarily removed from the synapse by astrocytic uptake via the transporters GLT-1 and GLAST. However, a fraction is also removed by neuronal uptake primarily mediated by GLT-1 activity. In the astrocyte, glutamate is converted into glutamine by the enzyme glutamine synthetase (GS) which is only found in astrocytes. Glutamine may be released from astrocytes through SNAT3/5 and is taken up by neurons primarily by SNAT1/7/8. Once taken up into the neurons, glutamine is converted by phosphate-activated glutaminase (PAG) into glutamate and the cycle is thereby completed. Note that SNAT1/7/8 are localized in the axon terminal for diagrammatic purposes to indicate expression in neurons. The SNATs expressed specifically in axon terminals have not been definitively identified (Conti and Melone, 2006; Erickson, 2017). Glutamate is also oxidatively metabolized in the TCA cycle in both neurons and astrocytes, primarily via the enzymes aspartate aminotransferase (AAT) and glutamate dehydrogenase (GDH).

Source publication
Article
Full-text available
Glutamate is the primary excitatory neurotransmitter of the brain. Cellular homeostasis of glutamate is of paramount importance for normal brain function and relies on an intricate metabolic collaboration between neurons and astrocytes. Glutamate is extensively recycled between neurons and astrocytes in a process known as the glutamate-glutamine cy...

Contexts in source publication

Context 1
... (MAS, see Fig. 3). Glutamate can also undergo oxidative deamination to α-ketoglutarate via the enzyme glutamate dehydrogenase (GDH), which serves as an anaplerotic pathway in both neurons and astrocytes. Finally, glutamate and glutamine are extensively recycled between neurons and astrocytes in a process called the glutamateglutamine cycle (see Fig. 2). In astrocytes, glutamate is converted into glutamine by fixation of NH 4 + via the enzyme glutamine synthetase (GS), an enzyme exclusively expressed in astrocytes. Conversely, glutamine is converted back into glutamate with the release of NH 4 + by the enzyme phosphate-activated glutamine (PAG), which is predominantly located in ...
Context 2
... glutamate participates in a highly active recycling process between presynaptic glutamatergic neurons and astrocytes, known as the glutamate-glutamine cycle ( Fig. 2) (Bak et al., 2006;Hertz, 2013;Hertz and Rothman, 2016). Astrocytes are closely associated with the glutamatergic synapse and are responsible for the majority of extracellular glutamate uptake, whereas a minor fraction is recovered by neuronal uptake (Hertz and Schousboe, 1987;Lehre and Danbolt, 1998;Zhou and Danbolt, 2013). Although ...
Context 3
... in astrocytes. De novo glutamate synthesis is dependent on sufficient anaplerosis, i.e. reactions providing a net increase in TCA cycle intermediates (Sonne- wald, 2014). The primary anaplerotic enzyme in the brain, pyruvate carboxylase (PC), is exclusively expressed in astrocytes and serves as the main pathway of de novo glutamate synthesis (Fig. 2) ( Schousboe et al., 2019;Yu et al., 1983;¨ Oz et al., 2004). The selective expression of PC in astrocytes, in combination with the essential role of astrocyte-derived glutamine, underlines the fact that neuronal glutamate homeostasis is under tight astrocytic control ( Schousboe et al., ...
Context 4
... leucine, isoleucine and valine are readily transported across the blood brain barrier and are important nitrogen donors for glutamate synthesis via BCAT activity (Sperringer et al., 2017;Yudkoff, 1997) which is crucial for de novo synthesis of glutamate ( Conway and Hutson, 2016). Since there is a net flow of glutamate from neurons to astrocytes (Fig. 2), the cell-specific metabolism of glutamate is an area of great interest as discussed in detail ...
Context 5
... of both the cytosolic and mitochondrial isoforms of AAT has been reported in both human AD brain samples and animal models ( Li et al., 2020;Mahajan et al., 2020;Puthiyedth et al., 2016;Savas et al., 2017). Lower activity or expression of AAT could disturb glutamate synthesis and metabolism, but could also have significant impact on MAS activity (Fig. 3) (McKenna et al., 2006), which in turn may contribute to the cerebral bioenergetic crisis of AD. Intriguingly, we recently found a selective reduction in astrocytic aspartate synthesis in hippocampal slices of 5xFAD mice (Andersen et al., 2021), which may indicate that astrocyte-specific metabolic deficiencies in AD disrupt aspartate and glutamate ...
Context 6
... et al., 2014;Carter, 1982;Hosp et al., 2017;Liévens et al., 2001;Tong et al., 2014). We have also recently reported reduced cerebral GS expression is the R6/2 mice ( Skotte et al., 2018). Interestingly, we also found decreased expression of the glutamine transporter SNAT3 ( Skotte et al., 2018), which is primarily expressed in astrocytes (Fig. 2). This could lead to a reduced capacity of astrocyte glutamine release, which may explain the reported accumulation of cerebral glutamine in HD. In the same study we also investigated functional metabolism in cerebral cortical and striatal slices of R6/2 mice. Surprisingly, we observed that glucose metabolism was largely maintained in ...

Similar publications

Article
Full-text available
Background Impaired brain energy metabolism has been observed in many neurodegenerative diseases, including Parkinson’s disease (PD) and multiple sclerosis (MS). In both diseases, mitochondrial dysfunction and energetic impairment can lead to neuronal dysfunction and death. CNM-Au8® is a suspension of faceted, clean-surfaced gold nanocrystals that...
Article
Full-text available
Background: Brain metabolic alterations and neuroinflammation have been reported in several peripheral inflammatory conditions and present significant potential for targeting with new diagnostic approaches and treatments. However, non-invasive evaluation of these alterations remains a challenge. Methods: Here, we studied the utility of a micro p...
Article
Full-text available
This is a tribute to John Edmond, professor emeritus of biological chemistry in the David Geffen School of Medicine at UCLA, a renowned neurochemist who had a leadership role in founding the ICBEM meeting series in 1993. John was known for his very warm and engaging personality and his innovative approaches to studying the developing brain and audi...
Article
Full-text available
The lack of biomarkers greatly limits the diagnosis and treatment of major depressive disorder (MDD). Endogenous L-carnitine (LC) and its derivative acetyl-L-carnitine (ALC) play antidepressant roles by improving brain energy metabolism, regulating neurotransmitters and neural plasticity. The levels of ALC in people and rodents with depression are...
Article
Full-text available
Objective: L-3-n-Butylphthalide (NBP) is used to treat moderate and severe acute ischemia stroke. A previous screening study indicates that XY03-EA, a novel derivative of NBP, is more potent than NBP in the oxyradical scavenging capacity. In this study, in vivo and in vitro ischemia/reperfusion (I/R) models were used to test whether the XY03-EA of...

Citations

... Gln bolsters the immune system, produces nicotinamide adenine dinucleotide phosphate hydrogen (NADPH), and promotes antioxidant (e.g., glutathione) production [17,18]. Gln and Glu can both be converted into PGlu via Glutaminyl Cyclase (QC) (Figure 1) [17,19,20]. Conversion to PGlu is significant due to the metabolite's association with deficits in special memory, working memory, and motor function [21]. ...
... One answer could involve frequency band analysis measured using an electroencephalogram (EEG). The electrical brain activity recorded from an EEG is categorized into frequency bands, measured in Hz, as follows: gamma , beta (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30), alpha (7)(8)(9)(10)(11)(12)(13), theta (4-7 Hz), and delta (0.1-4 Hz), with Hz ranges varying depending on the study [22]. Of these frequency bands, the alpha band, which is the dominant frequency, Figure 1. ...
... One answer could involve frequency band analysis measured using an electroencephalogram (EEG). The electrical brain activity recorded from an EEG is categorized into frequency bands, measured in Hz, as follows: gamma , beta (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30), alpha (7)(8)(9)(10)(11)(12)(13), theta (4-7 Hz), and delta (0.1-4 Hz), with Hz ranges varying depending on the study [22]. Of these frequency bands, the alpha band, which is the dominant frequency, has been extensively studied for its relevant clinical implications. ...
Article
Full-text available
Electroencephalogram (EEG) studies have suggested compensatory brain overactivation in cognitively healthy (CH) older adults with pathological beta-amyloid(Aβ42)/tau ratios during working memory and interference processing. However, the association between glutamatergic metabolites and brain activation proxied by EEG signals has not been thoroughly investigated. We aim to determine the involvement of these metabolites in EEG signaling. We focused on CH older adults classified under (1) normal CSF Aβ42/tau ratios (CH-NATs) and (2) pathological Aβ42/tau ratios (CH-PATs). We measured plasma glutamine, glutamate, pyroglutamate, and γ-aminobutyric acid concentrations using tandem mass spectrometry and conducted a correlational analysis with alpha frequency event-related desynchronization (ERD). Under the N-back working memory paradigm, CH-NATs presented negative correlations (r = ~−0.74–−0.96, p = 0.0001–0.0414) between pyroglutamate and alpha ERD but positive correlations (r = ~0.82–0.95, p = 0.0003–0.0119) between glutamine and alpha ERD. Under Stroop interference testing, CH-NATs generated negative correlations between glutamine and left temporal alpha ERD (r = −0.96, p = 0.037 and r = −0.97, p = 0.027). Our study demonstrated that glutamine and pyroglutamate levels were associated with EEG activity only in CH-NATs. These results suggest cognitively healthy adults with amyloid/tau pathology experience subtle metabolic dysfunction that may influence EEG signaling during cognitive challenge. A longitudinal follow-up study with a larger sample size is needed to validate these pilot studies.
... In recent years, it has been shown that neurons can produce ketone bodies from fatty acids and use fatty acids to produce energy via ß-oxidation [45]. In another study, it was observed that astrocytes in brain slices from mice can use C8 and C10 fatty acids for energy production and the synthesis of GABA [46]. SIRT4 is also predominantly localized in the mitochondria, and deacetylates and inactivates malonyl CoA decarboxylase (MCD). ...
Article
Full-text available
Pharmacotherapy is the therapeutic mainstay in epilepsy; however, in about 30% of patients, epileptic seizures are drug-resistant. A ketogenic diet (KD) is an alternative therapeutic option. The mechanisms underlying the anti-seizure effect of a KD are not fully understood. Epileptic seizures lead to an increased energy demand of neurons. An improvement in energy provisions may have a protective effect. C8 and C10 fatty acids have been previously shown to activate mitochondrial function in vitro. This could involve sirtuins (SIRTs) as regulatory elements of energy metabolism. The aim of the present study was to investigate whether ß-hydroxybutyrate (ßHB), C8 fatty acids, C10 fatty acids, or a combination of C8 and C10 (250/250 µM) fatty acids, which all increase under a KD, could up-regulate SIRT1, -3, -4, and -5 in HT22 hippocampal murine neurons in vitro. Cells were incubated for 1 week in the presence of these metabolites. The sirtuins were measured at the enzyme (fluorometrically), protein (Western blot), and gene expression (PCR) levels. In hippocampal cells, the C8, C10, and C8 and C10 incubations led to increases in the sirtuin levels, which were not inferior to a ßHB incubation as the ‘gold standard’. This may indicate that both C8 and C10 fatty acids are important for the antiepileptic effect of a KD. A KD may be replaced by nutritional supplements of C8 and C10 fatty acids, which could facilitate the diet.
... Astrocytes express various receptor and transporter proteins for neurotransmitters and possess the ability to release gliotransmitters themselves [4,5]. While their role in glutamate homeostasis is well established [6,7], their contribution to dopamine (DA) homeostasis remains an area of active investigation. ...
Article
Full-text available
Citation: Sočan, V.; Dolinar, K.; Kržan, M. Kinetic Properties and Pharmacological Modulation of High-and Low-Affinity Dopamine Transport in Striatal Astrocytes of Adult Rats. Int. J. Mol. Sci. 2024, 25, 5135. https://doi.org/10.3390/ ijms25105135 Academic Editors: Anna Stasiak and Dorota Łażewska Abstract: Astrocytes actively participate in neurotransmitter homeostasis by bidirectional communication with neuronal cells, a concept named the tripartite synapse, yet their role in dopamine (DA) homeostasis remains understudied. In the present study, we investigated the kinetic and molecular mechanisms of DA transport in cultured striatal astrocytes of adult rats. Kinetic uptake experiments were performed using radiolabeled [ 3 H]-DA, whereas mRNA expression of the dopamine, nore-pinephrine, organic cation and plasma membrane monoamine transporters (DAT, NET, OCTs and PMAT) and DA receptors D1 and D2 was determined by qPCR. Additionally, astrocyte cultures were subjected to a 24 h treatment with the DA receptor agonist apomorphine, the DA receptor antagonist haloperidol and the DA precursor L-DOPA. [ 3 H]-DA uptake exhibited temperature, concentration and sodium dependence, with potent inhibition by desipramine, nortriptyline and decynium-22, suggesting the involvement of multiple transporters. qPCR revealed prominent mRNA expression of the NET, the PMAT and OCT1, alongside lower levels of mRNA for OCT2, OCT3 and the DAT. Notably, apomorphine significantly altered NET, PMAT and D1 mRNA expression, while haloperidol and L-DOPA had a modest impact. Our findings demonstrate that striatal astrocytes aid in DA clearance by multiple transporters, which are influenced by dopaminergic drugs. Our study enhances the understanding of regional DA uptake, paving the way for targeted therapeutic interventions in dopaminergic disorders.
... Previous studies 30,36-38 have reported contradictory results (lower levels vs. higher levels) of glutamate in AD patients. Our findings of a negative relationship between glutamate levels in plasma and amyloid deposition in brain are inconsistent with the notion that elevated glutamate induces neurotoxicity, impacting neurons adversely 39 . Conversely, reduced glutamate levels could signify synaptic dysfunction and cognitive decline 40,41 . ...
Article
Full-text available
The metabolic implications in Alzheimer’s disease (AD) remain poorly understood. Here, we conducted a metabolomics study on a moderately aging Chinese Han cohort (n = 1397; mean age 66 years). Conjugated bile acids, branch-chain amino acids (BCAAs), and glutamate-related features exhibited strong correlations with cognitive impairment, clinical stage, and brain amyloid-β deposition (n = 421). These features demonstrated synergistic performances across clinical stages and subpopulations and enhanced the differentiation of AD stages beyond demographics and Apolipoprotein E ε4 allele (APOE-ε4). We validated their performances in eight data sets (total n = 7685) obtained from Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Religious Orders Study and Memory and Aging Project (ROSMAP). Importantly, identified features are linked to blood ammonia homeostasis. We further confirmed the elevated ammonia level through AD development (n = 1060). Our findings highlight AD as a metabolic disease and emphasize the metabolite-mediated ammonia disturbance in AD and its potential as a signature and therapeutic target for AD.
... In astrocytes, glutamate is metab olized to glutamine by glutamine synthetase (GS). The glutamate-glutamine cycle is necessary for the normal activity of the glutamatergic synapse [18]. A disruption of each of the above components can lead to pathologic changes and development of epilepsy. ...
... A disruption of each of the above components can lead to pathologic changes and development of epilepsy. Thus, GS inactivation leads to the development of seizures or neurodegeneration due to excitotoxicity [18]. During seizures, the dissociation of channels formed by Cx43 leads to the appearance of halfchannels, which increases the release of glutamate, ATP, and other compounds by astrocytes that pro mote neuronal excitability. ...
... In this regard, the increased expression of the Slc1a3 gene may indicate the compensatory mechanisms aimed at reducing the concentration of glutamate in the extracellular substance. Next, we analyzed changes in the expression of the Glul gene encoding glutamine synthetase (GS), which is a key enzyme of the glutamate-glutamine cycle necessary for the normal functioning of the glutamatergic synapse [18]. An increase in Glul expression was found in the dorsal and ventral hip pocampus. ...
... They also play an indispensable role in central nervous system (CNS) glutamate metabolism. It is well established that astrocytes can reuptake the overwhelming majority of synaptic glutamate, thereby preventing glutamate excitotoxicity [12]. In the CNS, glutamate clearance is mediated by excitatory amino acid transporters (EAATs), which are mainly expressed on astrocytes. ...
Article
Full-text available
Numerous neurological disorders share a fatal pathologic process known as glutamate excitotoxicity. Among which, ischemic stroke is the major cause of mortality and disability worldwide. For a long time, the main idea of developing anti-excitotoxic neuroprotective agents was to block glutamate receptors. Despite this, there has been little successful clinical translation to date. After decades of “neuron-centered” views, a growing number of studies have recently revealed the importance of non-neuronal cells. Glial cells, cerebral microvascular endothelial cells, blood cells, and so forth are extensively engaged in glutamate synthesis, release, reuptake, and metabolism. They also express functional glutamate receptors and can listen and respond for fast synaptic transmission. This broadens the thoughts of developing excitotoxicity antagonists. In this review, the critical contribution of non-neuronal cells in glutamate excitotoxicity during ischemic stroke will be emphasized in detail, and the latest research progress as well as corresponding therapeutic strategies will be updated at length, aiming to reconceptualize glutamate excitotoxicity in a non-neuronal perspective.
... Glutamatergic neurotransmission is responsible for many cognitive, motor, sensory, and autonomic nervous activities [220][221][222]. Neuroexcitotoxicity induced by glutamate has been demonstrated in a number of neurological and psychiatric disorders, including PD [223][224][225][226][227], epilepsy [228,229], traumatic brain injury [230,231], MS [232][233][234], AD [223,224,235,236], HD [223,[237][238][239], ALS [223,239,240], etc. ...
Article
Full-text available
Objective: L-carnitine (LC), a vital nutritional supplement, plays a crucial role in myocardial health and exhibits significant cardioprotective effects. LC, being the principal constituent of clinical-grade supplements, finds extensive application in the recovery and treatment of diverse cardiovascular and cerebrovascular disorders. However, controversies persist regarding the utilization of LC in nervous system diseases, with varying effects observed across numerous mental and neurological disorders. This article primarily aims to gather and analyze database information to comprehensively summarize the therapeutic potential of LC in patients suffering from nervous system diseases while providing valuable references for further research. Methods: A comprehensive search was conducted in PubMed, Web Of Science, Embase, Ovid Medline, Cochrane Library and Clinicaltrials.gov databases. The literature pertaining to the impact of LC supplementation on neurological or psychiatric disorders in patients was reviewed up until November 2023. No language or temporal restrictions were imposed on the search. Results: A total of 1479 articles were retrieved, and after the removal of duplicates through both automated and manual exclusion processes, 962 articles remained. Subsequently, a meticulous re-screening led to the identification of 60 relevant articles. Among these, there were 12 publications focusing on hepatic encephalopathy (HE), while neurodegenerative diseases (NDs) and peripheral nervous system diseases (PNSDs) were represented by 9 and 6 articles, respectively. Additionally, stroke was addressed in five publications, whereas Raynaud's syndrome (RS) and cognitive disorder (CD) each had three dedicated studies. Furthermore, migraine, depression, and amyotrophic lateral sclerosis (ALS) each accounted for two publications. Lastly, one article was found for other symptoms under investigation. Conclusion: In summary, LC has demonstrated favorable therapeutic effects in the management of HE, Alzheimer's disease (AD), carpal tunnel syndrome (CTS), CD, migraine, neurofibromatosis (NF), PNSDs, RS, and stroke. However, its efficacy appears to be relatively limited in conditions such as ALS, ataxia, attention deficit hyperactivity disorder (ADHD), depression, chronic fatigue syndrome (CFS), Down syndrome (DS), and sciatica.
... 8,9 Besides deficiencies of neurotransmitters caused by neurodegeneration, differences in the regulation of receptor expression and neurotransmitter metabolism might influence symptom prevalence as proposed for the pathophysiology of dyskinesias in PD. 10 Such receptor-neurotransmitter imbalance might be particularly relevant for glutamate and its receptors, the brain's primary excitatory neurotransmitter involved in many physiologic processes. [11][12][13][14] Although it has been suggested that glutamate is involved in the pathophysiology of RBD, 15 its contribution to the clinical phenotype of PD with RBD remains unclear. In addition to ionotropic glutamate receptors (including NMDA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and kainate receptors), G protein-coupled metabotropic glutamate receptors (mGluR) are paramount for the regulation of glutamate signaling, particularly in the motor circuitry of the basal ganglia. ...
... Thus, deeper insight into the underlying mechanism of this cellular process may provide a therapeutic window for the control of astrogliosis. Glutamate is the major excitatory neurotransmitter in the CNS [2], and its impaired clearance from the synaptic space can cause glutamate excitotoxicity, neuronal hyperexcitation, and damage [81]. Our results indicate that SOX9 overexpression promotes glutamate uptake, which could have potential therapeutic importance since glutamate-mediated excitotoxicity has been observed in various CNS pathologies, including TBI [6,7,65]. ...
Article
Full-text available
Astrocytes are the main homeostatic cells in the central nervous system, with the unique ability to transform from quiescent into a reactive state in response to pathological conditions by reacquiring some precursor properties. This process is known as reactive astrogliosis, a compensatory response that mediates tissue damage and recovery. Although it is well known that SOX transcription factors drive the expression of phenotype-specific genetic programs during neurodevelopment, their roles in mature astrocytes have not been studied extensively. We focused on the transcription factors SOX2 and SOX9, shown to be re-expressed in reactive astrocytes, in order to study the reactivation-related functional properties of astrocytes mediated by those proteins. We performed an initial screening of SOX2 and SOX9 expression after sensorimotor cortex ablation injury in rats and conducted gain-of-function studies in vitro using astrocytes derived from the human NT2/D1 cell line. Our results revealed the direct involvement of SOX2 in the reacquisition of proliferation in mature NT2/D1-derived astrocytes, while SOX9 overexpression increased migratory potential and glutamate uptake in these cells. Our results imply that modulation of SOX gene expression may change the functional properties of astrocytes, which holds promise for the discovery of potential therapeutic targets in the development of novel strategies for tissue regeneration and recovery.
... BCAAs undergo transamination with α-ketoglutarate catalysed by BCAA transaminase in the initial step of BCAA catabolism. This process results in the generation of glutamate, a key amino acid with diverse roles in cellular metabolism, neuro-transmission, and energy production [80]. The increased concentration of glutamate in diabetic patients, as revealed by many metabolite studies, suggests a potential link between glutamate function and the onset of T2DM [81][82][83]. ...